A study of potential pharmacokinetic and pharmacodynamic interactions between dextromethorphanquinidine and memantine in healthy volunteers

Clinical Drug Investigation

Volumn 32, Issue 8, 2012, Pages

  Pope, Laura E ^a   Schoedel, Kerri A ^b   Bartlett, Cynthia ^b   Sellers, Edward M ^c  

^a AVANIR PHARMACEUTICALS   (United States)

^b SYNEOS HEALTH   (United States)

^c Ventana Clinical Research Corporation   (Canada)

Author keywords

Dextromethorphan; drug interactions; memantine; pharmacokinetics; quinidine

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYTOCHROME P450 2D6; DEXTROMETHORPHAN PLUS QUINIDINE; DEXTRORPHAN; GAMMA GLUTAMYLTRANSFERASE; MEMANTINE;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DISEASE DURATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLATULENCE; HUMAN; INSOMNIA; LETHARGY; LOOSE FECES; MALE; MAXIMUM PLASMA CONCENTRATION; MENTAL INSTABILITY; MONOTHERAPY; NAUSEA; NORMAL HUMAN; OPEN STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PATIENT COMPLIANCE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SIDE EFFECT; SOMNOLENCE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; XEROSTOMIA;

ADULT; DEXTROMETHORPHAN; FEMALE; HUMANS; MALE; MEMANTINE; MIDDLE AGED; QUINIDINE; REFERENCE VALUES;

EID: 84863600343     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11633850-000000000-00000     Document Type: Article

References (33)

1. Schiffer R, Pope LE. Review of pseudobulbar affect including a novel and potential therapy. J Neuropsychiatry Clin Neurosci 2005 Fall; 17 (4): 447-454 (Pubitemid 41794037)
2. Wortzel HS, Oster TJ, Anderson CA, et al. Pathological laughing and crying: Epidemiology, pathophysiology and treatment. CNS Drugs 2008; 22 (7): 531-545 (Pubitemid 351822116)
3. Dark FL, McGrath JJ, Ron MA. Pathological laughing and crying. Aust N Z J Psychiatry 1996 Aug; 30 (4): 472-479 (Pubitemid 26312992)
4. Davison C, Kelman H. Pathologic laughing and crying. Arch Neurol Psychiatry 1939 Oct; 42 (4): 595-643
5. Calvert T, Knapp P, House A. Psychological associations with emotionalism after stroke. J Neurol Neurosurg Psychiatry 1998 Dec; 65 (6): 928-929 (Pubitemid 128710438)
6. Tateno A, Jorge RE, Robinson RG. Pathological laughing and crying following traumatic brain injury. J Neuropsychiatry Clin Neurosci 2004 Fall; 16 (4): 426-434 (Pubitemid 39648343)
7. Tang WK, Chen Y, Lam WW, et al. Emotional incontinence and executive function in ischemic stroke: A case-controlled study. J Int Neuropsychol Soc 2009 Jan; 15 (1): 62-68
8. Siddiqui MS, Fernandez HH, Garvan CW, et al. Inappropriate crying and laughing in Parkinson disease and movement disorders. World J Biol Psychiatry 2009; 10 (3): 234-240
9. Petracca GM, Jorge RE, Ació n L, et al. Frequency and correlates of involuntary emotional expression disorder in Parkinson's disease. J Neuropsych Clin Neurosci 2009 Fall; 21 (4): 406-412
10. Panitch HS, Thisted RA, Smith RA, et al., Pseudobulbar Affect in Multiple Sclerosis Study Group. Randomized, controlled trial of dextromethorphan/ quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol 2006 May; 59 (5): 780-787 (Pubitemid 43673155)
11. Brooks BR, Thisted RA, Appel SH, et al., AVP-923 ALS Study Group. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: A randomized trial. Neurology 2004 Oct; 63 (8): 1364-1370 (Pubitemid 39426266)
12. Pioro EP, Brooks BR, Cummings J, et al., Safety, Tolerability, and Efficacy Results Trial of AVP-923 in PBA Investigators. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol 2010 Nov; 68 (5): 693-702
13. Nuedexta [package insert]. Aliso Viejo (CA): AVANIR Pharmaceuticals, Inc; 2011
14. Choi DW, Peters S, Viseskul V. Dextrorphan and levorphanol selectively block N-methyl-D-aspartate receptormediated neurotoxicity on cortical neurons. J Pharmacol Exp Ther 1987 Aug; 242 (2): 713-720 (Pubitemid 17143508)
15. Werling LL, Keller A, Frank JG, et al. A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: Treatment of involuntary emotional expression disorder. Exp Neurol 2007 Oct; 207 (2): 248-257 (Pubitemid 47429659)
16. Musacchio JM, Klein M, Canoll PD. Dextromethorphan and sigma ligands: Common sites but diverse effects. Life Sci 1989; 45 (19): 1721-1732 (Pubitemid 19278813)
17. Pope LE, Khalil MH, Berg JE, et al. Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers. J Clin Pharmacol 2004 Oct; 44 (10): 1132-1142 (Pubitemid 39202458)
18. Walker FO, Hunt VP. An open label trial of dextromethorphan in Huntington's disease. Clin Neuropharmacol 1989 Aug; 12 (4): 322-330 (Pubitemid 19273668)
19. Zhang Y, Britto MR, Valderhaug KL, et al. Dextromethorphan: Enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6. Clin Pharmacol Ther 1992 June; 51 (6): 647-655
20. European Medicines Agency. Ebixa- (memantine) 10mg film-coated tablets: Summary of product characteristics [online]. Available from URL: Http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Informa tion/human/000463/WC500058763.pdf [Accessed 2011Oct 4]
21. Starkstein SE, Migliorelli R, Teson A, et al. Prevalence and clinical correlates of pathological affective display in Alzheimer's disease. J Neurol Neurosurg Psychiatry Jul 1995; 59 (1): 55-60
22. Grace AA, Camm AJ. Quinidine. N Engl J Med 1998 Jan; 338 (1): 35-45 (Pubitemid 28040538)
23. Fattinger K, Vozeh S, Ha HR, et al. Population pharmacokinetics of quinidine. Br J Clin Pharmacol 1991 Mar; 31 (3): 279-286
24. Rao N, Chou T, Ventura D, et al. Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: A single-center, multiple-dose, open-label study. Clin Ther 2005 Oct; 27 (10): 1596-1606 (Pubitemid 41739495)
25. Ebixa- (memantine). Product monograph. Lundbeck. 2002 [online]. Available from URL: Http://www.ebixa.com/con tent/downloadarea/pdf/monograph.pdf [Accessed 2011Oct 4]
26. Stüven T, Griese EU, Kroemer HK, et al. Rapid detection of CYP2D6 null alleles by long distance- and multiplexpolymerase chain reaction. Pharmacogenetics 1996 Oct; 6 (5): 417-421 (Pubitemid 26380097)
27. Hindmarch I, Shamsi Z, Stanley N, et al. A double-blind, placebo-controlled investigation of the effects of fexofenadine, loratadine and promethazine on cognitive and psychomotor function. Br J Clin Pharmacol 1999 Aug; 48 (2): 200-206 (Pubitemid 29349456)
28. Milovan D, Almeida L, Romach MK, et al. Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers. Epilepsy Behav 2010 Aug; 18 (4): 366-373
29. Collins JJ, De Luca CJ. Open-loop and closed-loop control of posture: A random-walk analysis of center-of-pressure trajectories. Exp Brain Res 1993; 95 (2): 308-318 (Pubitemid 23288339)
30. Beck AT, Steer AT, Ball R, et al. Comparison of Beck Depression Inventories -1A and -II in psychiatric outpatients. J Pers Assess 1996 Dec; 67 (3): 588-597 (Pubitemid 26382973)
31. Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: Psychometric properties. J Consult Clin Psychol 1988 Dec; 56 (6): 893-897 (Pubitemid 19008360)
32. Parrott AS, Hindmarch I. The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations: A review. Psychopharmacology (Berl) 1980; 71 (2): 173-179 (Pubitemid 11254055)
33. European Medicines Agency. Guideline on the investigation of bioequivalence. 2008 [online]. Available from URL: Http://www.ema.europa.eu/ docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003011.pdf [Accessed 2011 Jun 10]